^
    Back
    Association details:
    Biomarker:TPBG expression
    Cancer:Cervical Cancer
    Drug:ASN004 (Microtubule inhibitor, 5T4-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Mol Cancer Ther
    Title:

    ASN004, A 5T4-targeting scFv-Fc Antibody–Drug Conjugate with High Drug-to-Antibody Ratio, Induces Complete and Durable Tumor Regressions in Preclinical Models

    Excerpt:
    ASN004 was studied in a tumor xenograft model derived from the A431 (human cervical epidermoid, 5T4+; 88,000 binding sites per cell) tumor cell line….Complete tumor growth regression was observed for three ASN004 dose groups…
    DOI:
    https://doi.org/10.1158/1535-7163.MCT-20-0565